Globus Medical (GMED)
(Delayed Data from NYSE)
$50.75 USD
-0.45 (-0.88%)
Updated Apr 18, 2024 04:00 PM ET
After-Market: $50.74 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
Price, Consensus and EPS Surprise
GMED 50.75 -0.45(-0.88%)
Will GMED be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for GMED based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GMED
Why Globus Medical (GMED) is a Top Momentum Stock for the Long-Term
Why Globus Medical (GMED) is a Top Momentum Stock for the Long-Term
GMED: What are Zacks experts saying now?
Zacks Private Portfolio Services
Globus Medical (GMED) Gains From New Launches Amid Macro Issues
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Other News for GMED
RBC Capital Sticks to Its Buy Rating for Globus Medical (GMED)
Globus Medical Schedules First Quarter Earnings Release and Conference Call
What's Driving Masimo Corp's Surprising 17% Stock Rally?
Globus Medical Breaks Above 200-Day Moving Average - Bullish for GMED
Don't expect pandemic backlog to fuel orthopedic sales, says Needham